There’s no notification yet!
Background
Cannabis extracts have a wide therapeutic potential but in many countries they have not been approved for treatment in children so far.
Background: Open-label studies are not ideal for providing robust evidence for long-term maintenance of efficacy of medicines, especially where medicines provide symptom relief and where long-term use of a placebo may be problematic and not ethical.
Background: Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo‐controlled study of an oral antispasticity agent to use an enriched study design.
Symptoms relating to spasticity are common in multiple sclerosis (MS) and can be difficult to treat. We have investigated the efficacy, safety and tolerability of a standardized oromucosal whole plant cannabis‐based medicine (CBM) containing Δ‐9 tetrahydrocannabinol (THC) and cannabidiol (CBD), upon spasticity in MS.
